Home › Compare › PSCBF vs EQR

PSCBF vs EQR: Dividend Comparison 2026

PSCBF yields 1818.18% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PSCBF wins by $4103414683.80M in total portfolio value
10 years
PSCBF
PSCBF
● Live price
1818.18%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4103414683.84M
Annual income
$3,702,796,788,756,407.00
Full PSCBF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — PSCBF vs EQR

📍 PSCBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSCBFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSCBF + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PSCBF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSCBF
Annual income on $10K today (after 15% tax)
$154,545.45/yr
After 10yr DRIP, annual income (after tax)
$3,147,377,270,442,946.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, PSCBF beats the other by $3,147,377,270,439,699.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSCBF + EQR for your $10,000?

PSCBF: 50%EQR: 50%
100% EQR50/50100% PSCBF
Portfolio after 10yr
$2051707341.94M
Annual income
$1,851,398,394,380,113.20/yr
Blended yield
90.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

PSCBF
No analyst data
Altman Z
-5.7
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSCBF buys
0
EQR buys
0
No recent congressional trades found for PSCBF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSCBFEQR
Forward yield1818.18% ✓4.73%
Annual dividend / share$2.00$2.77 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$4103414683.84M ✓$40.5K
Annual income after 10y$3,702,796,788,756,407.00 ✓$3,819.61
Total dividends collected$4074760433.31M ✓$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: PSCBF vs EQR ($10,000, DRIP)

YearPSCBF PortfolioPSCBF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$192,518$181,818.18$11,248$547.57+$181.3K → PSCBF
2$3,477,331$3,271,336.99$12,701$666.53+$3.46M → PSCBF
3$58,943,217$55,222,471.89$14,405$814.59+$58.93M → PSCBF
4$937,891,469$874,822,227.57$16,413$999.84+$937.88M → PSCBF
5$14,012,869,532$13,009,325,660.38$18,795$1,232.92+$14012.85M → PSCBF
6$196,647,994,247$181,654,223,846.76$21,639$1,527.95+$196647.97M → PSCBF
7$2,592,865,386,485$2,382,452,032,641.56$25,057$1,903.80+$2592865.36M → PSCBF
8$32,132,661,421,271$29,358,295,457,731.54$29,197$2,385.87+$32132661.39M → PSCBF
9$374,409,247,740,494$340,027,300,019,734.44$34,250$3,008.70+$374409247.71M → PSCBF
10$4,103,414,683,838,736$3,702,796,788,756,407.00$40,467$3,819.61+$4103414683.80M → PSCBF

PSCBF vs EQR: Complete Analysis 2026

PSCBF — Stock

Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.

Full PSCBF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this PSCBF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSCBF vs SCHDPSCBF vs JEPIPSCBF vs OPSCBF vs KOPSCBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.